Phase 3 Antipsychotic Candidate Pimavanserin Fails to Achieve Primary Efficacy Endpoint
March 12th 2024Pimavanserin failed to achieve the primary efficacy endpoint of control of negative symptoms in patients with schizophrenia in the ADVANCE-2 trial. Acadia Pharmaceuticals will not pursue further research.
Fire and Ice Serendipitously Greet the Release of “Dune: Part Two”
March 4th 2024Over the last century and even longer, we have taken a useful fossil fuel energy road that has also led to the problematic adverse effects of acute and long-term disasters. Is this reflected in current popular films like “Dune: Part Two”?